ライフサイエンスコーパス: FVC

1 FVC measurements may not be appropriate for monitoring d

2 FVC missed 71.4% of dysplastic lesions per lesion wherea

3 FVC modeling, including 1,960 individuals, yielded simil

4 FVC% has acceptable test-retest reliability, and we have

5 FVC% improvement by >/=MCID was associated with either s

6 ce -0.78 [95% CI -0.96 to -0.61], p<0.0001), FVC (-0.15 [0.98] vs -0.38 [1.18], -0.25 [-0.40 to -0.10

7 as FUSE missed 25.0% per lesion (P = .0001); FVC missed 75.0% of dysplastic lesions per subject and F

8 d (FEV(1) -0.011L, [95% CI -0.05 to 0.028L], FVC -0.012L [95% CI -0.060 to 0.036] and FEV(1)/FVC rati

9 confidence interval (CI) -0.104 to -0.032), FVC (adj. difference -0.043L, 95% CI -0.086 to -0.0009)

10 lung function parameters in children (FEV(1) FVC(%pred) and FEF(25-75%pred) ), thus lower sEV-miRNA l

11 a significant lower lung function (FEV(1) , FVC), higher FeNO and higher risk of sensitization at 8

12 sure up to 3 months after birth, on FEV(1) , FVC, and FEV(1) /FVC ratio at 12 and 18 years.

13 rs overall had lower lung function (FEV(1) , FVC; P < .05).

14 expiratory flow (FEF(25%-75%) ) and FEV(1) /FVC ratio (Coef.

15 hout sensitization including a lower FEV(1) /FVC ratio (p < .05).

16 hs after birth, on FEV(1) , FVC, and FEV(1) /FVC ratio at 12 and 18 years.

17 At age 8 years, FEV(1) /FVC was significantly lower and FeNO significantly highe

18 tly diminished in the FE trajectory (FEV(1) /FVC, mean [95%CI]: 89.9% [89.3-90.5] vs. 88.1% [87.3-88.

19 cid [DHA]) were evaluated with PFTs (FEV(1), FVC, and FEV(1)/FVC) in meta-analyses across seven cohor

20 Mepolizumab did not affect FEV(1), FVC, and fractional exhaled nitric oxide, neither at bas

21 FEV(1), FVC, fractional exhaled nitric oxide, symptom scores (as

22 A postbronchodilator FEV(1)-FVC ratio less than 0.70 is required for a diagnosis of

23 urrent and former smokers with PRISm (FEV(1)/FVC >= 0.7 and FEV1 < 80%) in COPDGene was used to strat

24 st-bronchodilator FEV(1) (P = 0.007), FEV(1)/FVC (P = 0.003), and greater computed tomography-based e

25 rozygotes (ZS/ZV(R); n = 7) had lower FEV(1)/FVC (P = 0.02) and forced expiratory flow, midexpiratory

26 [95% CI], 0.07 [0.03 to 0.10]), lower FEV(1)/FVC (z-score difference [95% CI], -0.05 [-0.09 to -0.01]

27 term birth) was associated with lower FEV(1)/FVC and FEF(25-75%).

28 zard ratios (HR) markedly, e.g. for a FEV(1)/FVC below 0.7 from 1.55 [95% confidence-interval (CI) 1.

29 ated associations between the GRS and FEV(1)/FVC by 100% and 60% in MESA and SPIROMICS, respectively.

30 86-4.76%; P = 0.0047), 11.02% greater FEV(1)/FVC decline (95% CI, 4.43-17.62%; P = 0.0011), and 15% i

31 both subtypes correlated with future FEV(1)/FVC decline (r = -0.16 [P < 0.001] in the Tissue->Airway

32 (1)/FVC, and the effect of smoking on FEV(1)/FVC differs among the associated genotypes.

33 hase only in boys and lower levels of FEV(1)/FVC in both sexes.

34 intervals: 1.21-1.88), while reduced FEV(1)/FVC increases the risk of adenocarcinoma (OR = 1.17, 1.0

35 Early COPD was defined as FEV(1)/FVC less than the lower limit of normal in individuals u

36 VC was performed for individuals with FEV(1)/FVC ratio >= 70 in the Korea Associated Resource cohort

37 cted (-14.3%; P = 0.0092) and a lower FEV(1)/FVC ratio (-0.075; P = 0.0041) in SZ-AATD.

38 ], -0.25 [-0.40 to -0.10], p=0.0012), FEV(1)/FVC ratio (0.14 [1.10] vs -0.64 [1.35], -0.74 [-0.85 to

39 6 to -0.0009) and post-bronchodilator FEV(1)/FVC ratio (adj.

40 asthma severity (P = 0.02), and lower FEV(1)/FVC ratio (P = 0.01).

41 CI], 0.07 [0.04 to 0.10]), and lower FEV(1)/FVC ratio (z-score difference [95% CI], -0.07 [-0.10 to

42 -0.012L [95% CI -0.060 to 0.036] and FEV(1)/FVC ratio -0.0012 [95% CI -0.0072 to 0.0047L]).

43 The combination of normal FEV(1)/FVC ratio, airways responsiveness, and serum eosinophil

44 (FEV(1), forced vital capacity [FVC], FEV(1)/FVC ratio, and forced expiratory flow at 25-75% of FVC [

45 racting with pack-years of smoking on FEV(1)/FVC ratios in individuals with normal lung function.

46 and two thirds of girls with baseline FEV(1)/FVC ratios of 90% or greater were in remission at adulth

47 nome-wide interaction study (GWIS) on FEV(1)/FVC was performed for individuals with FEV(1)/FVC ratio

48 volume in 1 s/forced vital capacity (FEV(1)/FVC) but not FVC was related to mortality after adjustme

49 evaluated with PFTs (FEV(1), FVC, and FEV(1)/FVC) in meta-analyses across seven cohorts from the Coho

50 (1)), Forced Vital Capacity (FVC) and FEV(1)/FVC).

51 enes, of which 36 (16 for FVC, 19 for FEV(1)/FVC, and one for both) had not been identified in the la

52 n the 6p21 region are associated with FEV(1)/FVC, and the effect of smoking on FEV(1)/FVC differs amo

53 sociation between gene expression and FEV(1)/FVC.

54 fluence lung development with FVC and FEV(1)/FVC.

55 o of FEV(1) to forced vital capacity (FEV(1)/FVC: r(g) = 0.137, p = 2.0 x 10(-12)).

56 omposite mortality, hospitalization, and 10% FVC decline.

57 o 0.38, girls: 0.18 L, 95% CI 0.12 to 0.25), FVC (boys: 0.36 L, 95% CI 0.27 to 0.44, girls: 0.22 L, 9

58 tion of bilateral LT patients do not achieve FVC>80% predicted.

59 oes not predict survival, failure to achieve FVC>80% predicted during the first year was independentl

60 elated to baseline FVC% and increased at all FVC levels below 100%.

61 Although one-half patients achieved an FVC>80% predicted (49%), 1 in 5 (19%) remained below 60%

62 Although one-half patients achieved an FVC>80% predicted (49%), 1 in 5 (19%) remained below 60%

63 Patients with an FVC of <80% had an increased risk of death versus patien

64 beta=-0.0012 (95% CI: -0.0019, -0.0006) and FVC: beta=-0.0022 (95% CI: -0.0031, -0.0014) per BMI-inc

65 A were positively associated with FEV(1) and FVC (P < 0.025), with evidence for effect modification b

66 xposure was associated with lower FEV(1) and FVC compared with those with no in utero tobacco exposur

67 r regression was used to estimate FEV(1) and FVC from age 11 to 15 years in 2,120 adolescents across

68 ned at 1994 to 1997 NO(2) levels, FEV(1) and FVC growth were estimated to have been reduced by 2.7% (

69 tobacco was associated with lower FEV(1) and FVC longitudinally from 6 to 24 years (mean difference,

70 Year 30 FEV(1) and FVC were lower in the highest level of TLR5 compared to

71 correlated inversely with the FEV(1) (%) and FVC (%) values.

72 had faster declines in FEV1 (r = -0.16) and FVC (r = -0.26) and slower declines in FEV1:FVC ratio (r

73 fidence interval [CI], -1.357 to -0.296) and FVC% predicted (-0.817; 95% CI, -1.357 to -0.276), but s

74 27.6, -3.3 per doubling of pollen count) and FVC (-20.8 mL; -35.4, -6.1) at 12 years, but not at 18 y

75 gnificantly associated with reduced FEV1 and FVC (P < .05 for both).

76 0.5 z-scores ( approximately 5%) in FEV1 and FVC compared with African American peers from the third

77 patients with concurrent decline in FEV1 and FVC had significantly higher PRM(PD) than control subjec

78 restrictive impairment with reduced FEV1 and FVC in 75% of the patients.

79 and among groups based on the best FEV1 and FVC measurements (>80%, 60%-80%, and <60% predicted).

80 and among groups based on the best FEV1 and FVC measurements (>80%, 60-80% and <60%predicted).

81 owding, and pollution exposure) and FEV1 and FVC trajectories between ages 43 and 60-64 years were in

82 eading to a proportionately smaller FEV1 and FVC without respiratory impairment, as shown by the norm

83 ticipants with COPD, a reduction in FEV1 and FVC, and an increase in R5-20 were associated with an in

84 fe exposures impact on both midlife FEV1 and FVC.

85 rter LTL was associated with lower FEV1% and FVC% at baseline.

86 tified a mean of 0.37 dysplastic lesions and FVC identified a mean of 0.13 dysplastic lesions (P = .0

87 io of at least the lower limit of normal and FVC of <80% predicted) using modified Poisson regression

88 xamined in relation to FEV(1)% predicted and FVC% predicted at ages 8 (n = 5,276) and 15 (n = 3,446)

89 Low FEV(1)% predicted and FVC% predicted were also associated with increased demen

90 d reduced FEV1 (p = 5.69E-18, MR-PRESSO) and FVC (6.02E-22, MR-PRESSO).

91 AP)], brachial artery blood flow ( Q (BA) ), FVC ( Q (BA) /MAP) and MSNA burst frequency were measure

92 In patients with normal-range baseline FVC (80-100%), the 5- and 10-year survival rates correla

93 SMR was inversely related to baseline FVC% and increased at all FVC levels below 100%.

94 tion, and annual bronchoscopy findings, best FVC (% predicted) during the first year after LT was ind

95 latory defect, survival worsened as the best FVC (% predicted) got lower (>80: 80.8%; 60-80: 63.3%; <

96 latory defect, survival worsened as the best FVC (% predicted) got lower (>80: 80.8%; 60-80: 63.3%; <

97 We examined the associations between FVC/TLC(CT) quartiles and (1) baseline characteristics,

98 The ratio of post-bronchodilator FVC and TLC(CT) from chest CT (FVC/TLC(CT)) among curren

99 y whether lung function decline, assessed by FVC and FEV1, is accelerated in women who undergo menopa

100 ed to groups that underwent FUSE followed by FVC.

101 atory volume (FEV1%), forced vital capacity (FVC%), and the FEV1/FVC ratio.

102 metric pattern [60 <= forced vital capacity (FVC) < 80% predicted] vs. 21.2% with a moderate-to-sever

103 one second (FEV(1)), Forced Vital Capacity (FVC) and FEV(1)/FVC).

104 rcentage of predicted forced vital capacity (FVC) and stabilised 6-min walking distance compared with

105 spiratory cycles, the Forced Vital Capacity (FVC) and the Forced Expiratory Volume in one second (FEV

106 resulted from a lower forced vital capacity (FVC) in HIV-infected participants but similar 1-second f

107 FEV1 and its ratio to forced vital capacity (FVC) in never-smokers.

108 iated with changes in forced vital capacity (FVC) in two cohorts.

109 , a percent predicted forced vital capacity (FVC) of 45% or higher and percent predicted carbon monox

110 rcentage of predicted forced vital capacity (FVC) of 55% or greater were enrolled and randomly assign

111 the past 3 years and forced vital capacity (FVC) of 80% predicted or higher were eligible to partici

112 ociation guidelines), forced vital capacity (FVC) of at least 45%, 6MWD of 150-450 m, WHO functional

113 D was defined as FEV1/forced vital capacity (FVC) of less than 70% and less than the lower limit of n

114 wer decrease in their forced vital capacity (FVC) over time as compared with untreated ALS patients,

115 evels with FEV(1) and forced vital capacity (FVC) percent predicted.

116 me in 1-second (FEV1)/forced vital capacity (FVC) ratio <0.7.

117 econd (FEV(1))-to-functional vital capacity (FVC) ratio (-1.7 vs -0.7) and greater progression in qua

118 The degree of FEV(1)/forced vital capacity (FVC) ratio impairment was the largest predictor of asthm

119 Forced vital capacity (FVC) was associated with moderate-to-vigorous physical a

120 n 1 second (FEV1) and forced vital capacity (FVC) were lower in the HIV+ compared to the HIV- adolesc

121 rpg) was defined as a forced vital capacity (FVC) z score of less than -1.64 or an increase in FVC of

122 in 1 second (FEV(1)), forced vital capacity (FVC), and forced expiratory flow at 25-75% of the pulmon

123 e in 1 second (FEV1), forced vital capacity (FVC), and physical activity were assessed in 2 populatio

124 1), primary outcome), forced vital capacity (FVC), and respiratory or allergic symptoms.

125 e in 1 second (FEV1), forced vital capacity (FVC), and their ratio (FEV1:FVC).

126 al rate of decline in forced vital capacity (FVC), assessed over a 52-week period.

127 function parameters (forced vital capacity (FVC), pre- and postbronchodilator FEV1, residual volume

128 tratified by baseline forced vital capacity (FVC), serum LOXL2 (sLOXL2) concentrations, and pirfenido

129 one-second (FEV1) and forced vital capacity (FVC).

130 +, and having reduced forced vital capacity (FVC).

131 econd (FEV(1), %) and forced vital capacity (FVC, %) values.

132 lume in 1 s [FEV1] to forced vital capacity [FVC] <70%, bronchodilator reversibility >/=12%, fraction

133 bronchodilator FEV(1)/forced vital capacity [FVC] ratio <=0.70) and a specialist-verified diagnosis o

134 rst second [FEV1] and forced vital capacity [FVC]) and a decrease in pulse wave velocity (PWV) and au

135 ow variables (FEV(1), forced vital capacity [FVC], FEV(1)/FVC ratio, and forced expiratory flow at 25

136 ding correlation with concurrently collected FVC% predicted and the ability to discriminate between p

137 ut conventional forward-viewing colonoscopy (FVC) detects dysplasia with low levels of sensitivity.

138 oss-over, tandem colonoscopy study comparing FVC vs FUSE in 52 subjects with IBD undergoing surveilla

139 ly-inducing retrovirus Friend virus complex (FVC) infection, we find that while CD169 promoted draini

140 We assessed forearm vascular conductance (FVC) during rhythmic handgrip exercise under control con

141 calculated changes in vascular conductance (FVC) to intra-arterial infusion of phenylephrine (PE; al

142 calculated changes in vascular conductance (FVC) to local intra-arterial infusion of ACh (endotheliu

143 calculated changes in vascular conductance (FVC) to local intra-arterial infusion of phenylephrine (

144 ermodilution), forearm vascular conductance (FVC, venous occlusion plethysmography) and cutaneous vas

145 low and either forearm vascular conductance (FVC; regional sNVT) or diastolic blood pressure (systemi

146 By contrast, FVC was inversely correlated with annual NO(2) (-0.0023

147 ronchodilator FVC and TLC(CT) from chest CT (FVC/TLC(CT)) among current and former smokers with PRISm

148 Thus, CD169 plays a protective role during FVC pathogenesis by reducing viral dissemination to eryt

149 ]), mean FEV1 (-166 ml [-332, -1]) and FEV1 /FVC ratio (-4.6%, [-8.1, -1.1]) at 12 years.

150 e AA/AG genotypes had a 5% decrease in FEV1 /FVC (P<.001).

151 es (AA/AG), were associated with lower FEV1 /FVC in subjects with asthma (beta=-1.25, CI: -2.14,-0.35

152 a status and the PAI-1 polymorphism on FEV1 /FVC (P=.03).

153 .05), but not with FEV1 (% predicted), FEV1 /FVC or bronchodilator reversibility.

154 ed as post-bronchodilator spirometric (FEV1 /FVC) ratio <lower limit of normal.

155 The decrease in the FEV1 /FVC ratio associated with the risk genotype was modified

156 average annual rates of change in BMI, FEV1, FVC, and FEV1:FVC ratio were 0.22 kg/m2/year, -25.50 mL/

157 bronchodilator and post-bronchodilator FEV1, FVC, FEV1/FVC, and maximum mid-expiratory flow (MMEF).

158 greater (OR, 1.72; 95% CI, 1.14-2.59), FEV1/FVC ratio decrements (OR, -0.22 SDU; 95% CI, -0.36 to -0

159 but the proportion of patients with an FEV1/FVC ratio <0.7 decreased at 6, 12, 18, and 24 months (55

160 w limitation phenotype (A Limit) had an FEV1/FVC z score of less than -1.64 but not A Trpg.

161 lution computed tomographic images, and FEV1/FVC ratios less than 0.8 or greater than 0.9 (<0.7 or >0

162 Associations between smoking and FEV1/FVC ratios were different between asthma phenotypes (int

163 DLCO, FEV1, and FEV1/FVC were found to be valuable parameters in determining

164 hysematous changes were DLCO, FEV1, and FEV1/FVC, in that order.

165 Airway obstruction was defined as FEV1/FVC ratio <0.7.

166 as greatest for subjects whose baseline FEV1/FVC value was closest to the diagnostic threshold, and t

167 ically defined as a post-bronchodilator FEV1/FVC less than the lower limit of normal.

168 hese key genes to successfully estimate FEV1/FVC ratios across patients, via support-vector-machine r

169 s were negatively associated with FEV1, FEV1/FVC, and MMEF.

170 ator and post-bronchodilator FEV1, FVC, FEV1/FVC, and maximum mid-expiratory flow (MMEF).

171 lso significantly associated with lower FEV1/FVC (P = 0.04), its contribution relative to PRM(FSA) in

172 Biomass was associated with lower FEV1/FVC (raw values -7.0, p = 0.04; GLI pp -7.62, p = 0.05,

173 changed FEV1 (P = 0.94), yielding lower FEV1/FVC ratios (P < 0.001).

174 nourished African children had a normal FEV1/FVC ratio but significant reductions of approximately 0.

175 tory impairment, as shown by the normal FEV1/FVC ratio.

176 The lowest quartile of FEV1/FVC ratio at 7 years was associated with ACOS (odds rati

177 ere shown to have an additive effect on FEV1/FVC levels in the genetic risk score analysis; were asso

178 ow-up (defined as a postbronchodilation FEV1/FVC ratio of at least the lower limit of normal and FVC

179 ociated with reduced FEV1 to FVC ratio (FEV1/FVC), hyperinflation, and alveolar enlargement, but litt

180 %/year, 95%CI = [0.05-0.87]) and in the FEV1/FVC ratio (0.19%/year, 95%CI = [0.03-0.36]).

181 We identified associations between the FEV1/FVC ratio and 5 common genetic variants in the identific

182 ges in the lungs of PLWH when using the FEV1/FVC ratio as single diagnostic measure.

183 , forced vital capacity (FVC%), and the FEV1/FVC ratio.

184 The FEV1/FVC remained unchanged over time, but the proportion of

185 ationship of the PAI-1 risk allele with FEV1/FVC by multivariate linear regression, stratified by ast

186 rations were negatively associated with FEV1/FVC ratio (P < .05).

187 C42EP4 and DOCK5 transcript counts with FEV1/FVC ratio together support a role of CDC42 in the TH1 po

188 rates of change in BMI, FEV1, FVC, and FEV1:FVC ratio were 0.22 kg/m2/year, -25.50 mL/year, -21.99 m

189 Defining airflow obstruction as FEV1:FVC less than 0.70 provided discrimination of COPD-relat

190 uction, which was defined by a baseline FEV1:FVC less than a range of fixed thresholds (0.75 to 0.65)

191 in the first second to vital capacity (FEV1:FVC) less than 0.70 with respiratory symptoms.

192 st second to the forced vital capacity (FEV1:FVC) of less than 0.70, yet this fixed threshold is base

193 The optimal fixed FEV1:FVC threshold was defined by the best discrimination for

194 FVC (r = -0.26) and slower declines in FEV1:FVC ratio (r = 0.11) (all P values < 0.0001).

195 These results support the use of FEV1:FVC less than 0.70 to identify individuals at risk of cl

196 vital capacity (FVC), and their ratio (FEV1:FVC).

197 630 children who completed spirometry, FEV1:FVC was less than 70% in ten (2%) children, of whom only

198 We identified 55 genes, of which 36 (16 for FVC, 19 for FEV(1)/FVC, and one for both) had not been i

199 and we have provided the MCID estimates for FVC% in SSc-ILD based changes at 12 months from baseline

200 clinically important differences (MCID) for FVC% predicted in the Scleroderma Lung Study I and II.

201 e similar (21.2 min for FUSE vs 19.1 min for FVC; P = .32), but withdrawal time was significantly lon

202 e derived a group-based trajectory model for FVC progression in ALS, which validated against the outc

203 mates for the pooled cohort at 12 months for FVC% improvement ranged from 3.0 % to 5.3% and for worse

204 and post-menopausal women, in particular for FVC, beyond the expected age change.

205 we evaluated the test-retest reliability for FVC% predicted (FVC%; screening vs. baseline) using intr

206 significantly lower for FUSE (0.19) than for FVC (0.83; P < .0001).

207 ficantly longer for FUSE (15.8 min) than for FVC (12.0 min) (P = .03).

208 edicted and lower limit of normal values for FVC and FEV1 than those in other Hispanic/Latino backgro

209 hildren in the caffeine group had values for FVC below the fifth centile (11% vs. 28%; odds ratio, 0.

210 Mortality was lower in the very high FVC/TLC(CT) quartile relative to the other quartiles com

211 nterval, 0.44-0.79; P trend < 0.0001] higher FVC at 15 yr than boys in the lowest trajectory).

212 beta = 3.09; 95% CI = 0.58-5.59 and a higher FVC percent predicted (beta = 2.77; 95% CI = 0.47-5.06).

213 per SD score increase, respectively), higher FVC (z-score difference [95% CI], 0.19 [0.17 to 0.22] an

214 f fat mass index, was associated with higher FVC (z-score difference [95% CI], 0.07 [0.03 to 0.10]),

215 h or a categorical decrease from baseline in FVC % predicted, in the intention-to-treat population, i

216 rimary endpoint was mean predicted change in FVC from baseline over 24 weeks, measured by daily home

217 Over 24 weeks, predicted median change in FVC measured by home spirometry was -87.7 mL (Q1-Q3 -338

218 Over 24 weeks, predicted mean change in FVC measured by site spirometry was lower in patients gi

219 Secondary endpoints were change in FVC measured by site spirometry, proportion of patients

220 The adjusted rate of change in FVC over 12 weeks was 5.9 mL in the nintedanib group and

221 lysis, the adjusted annual rate of change in FVC was -52.4 ml per year in the nintedanib group and -9

222 ities are modestly correlated with change in FVC.

223 ith disease progression (absolute decline in FVC >=10% predicted or death) over 52 weeks.

224 1 (P < 0.001) and 1.55 ml/yr less decline in FVC (P < 0.001).

225 P < 0.001) and 3.27 ml/yr greater decline in FVC (P < 0.001).

226 vely, the adjusted annual rate of decline in FVC in patients treated with placebo was -225.7 and -221

227 group were less likely to have a decline in FVC of more than 5% (odds ratio [OR] 0.42 [95% CI 0.25 t

228 ce in the adjusted annual rate of decline in FVC was 117.0 ml/yr (95% confidence interval, 76.3-157.8

229 mic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clin

230 associated with a reduced rate of decline in FVC.

231 2.0-15 mL decrease) and a 16 ml decrease in FVC (95% CI: 7.0-24 mL decrease) per 1 kg/m(2) higher BM

232 centration was associated with a decrease in FVC (forced vital capacity) and FEV1 (forced expiratory

233 associated with a 3.7% absolute decrement in FVC% (95% confidence interval [CI] = 0.9-6.6%), a 1.6-fo

234 with a significant (p=0.0050) improvement in FVC in the Yale cohort.

235 wth (95% CI, 2.8-5.9) and a 7.1% increase in FVC growth (95% CI, 5.7-8.6).

236 z score of less than -1.64 or an increase in FVC of 10% of predicted value or greater with bronchodil

237 FEV(1) in children and adults, and increased FVC in adults.

238 ow obstruction was associated with increased FVC (P = 0.004) but unchanged FEV1 (P = 0.94), yielding

239 truction, aging is associated with increased FVC and CT-defined functional small airway abnormality r

240 PRISm at baseline (n = 1,131), the very low FVC/TLC(CT) quartile was associated with increased gas t

241 The very low FVC/TLC(CT) quartile was associated with increased total

242 lergic sensitisation, elevated IgE and lower FVC in childhood, which may reflect effects of lower pre

243 The lower FVC in HIV-infected participants could indicate HIV-rela

244 (frequency, ~80%) was associated with lower FVC (P(SNP) = 2.1 x 10(-9); beta(SNP) = -161.0 ml), and

245 he third trimester was associated with lower FVC% predicted (-1.312; 95% CI, -2.100 to -0.525).

246 The adjusted mean FVC decline was increased by -10.2 ml/yr (95% confidence

247 At baseline, mean FVC was 97.5% (SD 13.5) predicted.

248 e cohort was 69 +/- 7.60 years, and the mean FVC% predicted was 71 +/- 20.0.

249 s/forced vital capacity (FEV(1)/FVC) but not FVC was related to mortality after adjustment for physic

250 tio, and forced expiratory flow at 25-75% of FVC [FEF(25-75%)]) were converted to Z scores and analys

251 forced expiratory flow after exhaling 75% of FVC or asthma.

252 esponses, resulting in efficient clearing of FVC-infected cells.

253 is study sought to categorize progression of FVC after presentation to an outpatient ALS clinic.Objec

254 iated with higher levels and growth rates of FVC, FEV(1), and forced expiratory flow, midexpiratory p

255 Reliability of FVC%, assessed at a mean of 34 days, was 0.93 for the po

256 Main Results: We found three trajectories of FVC over time, termed "stable low," "rapid progressor,"

257 The primary outcome was trajectory of FVC over time in months.Measurements and Main Results: W

258 We examined the utility of FVC/TLC in identifying features of obstructive lung dise

259 D estimates for improvement and worsening of FVC% with patient reported outcomes (PROs) and computer-

260 ypes of ALS respiratory progression based on FVC trajectories over time.Methods: We derived a group-b

261 ha-T or gamma-T with mid-childhood FEV(1) or FVC.

262 h, lung transplantation, hospitalization, or FVC decline for those with an LTL less than the 10th per

263 e endpoints (death, lung transplantation, or FVC decline) for those with an LTL less than the 10th pe

264 e-to-severe restrictive spirometric pattern [FVC < 60% predicted], P for trend test < 0.001).

265 clinical and lung function biomarkers (PEF, FVC,FEV(1)), we estimated this loss of adaptive capacity

266 ta [SE], 1.5 [0.61]; P = .02) and percentage FVC (beta [SE], 5.2 [2.2]; P = .02) for selected vitamin

267 ajectories were correlated with postbaseline FVC trajectory (r = -0.30, 95% CI = -0.46 to -0.11, P =

268 decline reduced for percentage of predicted FVC (from -8.7% per year in weeks 0-28 to -0.9% per year

269 d and the effects on percentage of predicted FVC and 6-min walking distance were persistent on contin

270 ges from baseline in percentage of predicted FVC and 6-min walking distance, with descriptive statist

271 nge from baseline in percentage of predicted FVC at week 48.

272 duced the decline in percentage of predicted FVC by 60.3% at week 48 (mean change from baseline -2.9%

273 ine from baseline in percentage of predicted FVC of >=10%, or death) at week 48 was a key secondary e

274 t, with a decline in percentage of predicted FVC of -3.6% per year and in 6-min walking distance of -

275 01; 1.2% decrease in percentage of predicted FVC; 95% CI, 0.6-1.8%; P < 0.001) and decreased diffusin

276 ute or relative decline in percent predicted FVC measured by clinic-based spirometry, change in perce

277 test-retest reliability for FVC% predicted (FVC%; screening vs. baseline) using intra-class correlat

278 Reduced FVC/TLC(CT) ratio in PRISm is associated with increased

279 ography imaging, reduced Dl(CO), and reduced FVC.

280 5% was associated with significantly reduced FVC decline over 48 weeks versus no emphysema or emphyse

281 n this cohort, C-PHIV and those with reduced FVC have shorter granulocyte TL, possibly the result of

282 ysema extent (28 to 65%) showed the smallest FVC decline, with a difference of 3.32% at Week 48 versu

283 avity)) in smokers but not in never smokers: FVC differences for 10 min increase in MVPA were 58.6 (9

284 Under control conditions, steady-state FVC was augmented in high vs. low fibre recruitment (211

285 Factors that decrease the FVC could obscure emphysematous changes in the lungs of

286 LE: Aging is associated with reduced FEV1 to FVC ratio (FEV1/FVC), hyperinflation, and alveolar enlar

287 e assigned randomly to groups that underwent FVC followed by FUSE, and 25 were assigned to groups tha

288 is was associated with greater lung volumes (FVC, vital capacity, and total lung capacity) and lesser

289 We compared FUSE vs FVC in the detection of dysplasia in patients with IBDs.

290 d to the erythroblasts in the red pulp where FVC manifests its pathogenesis.

291 and CVC were similar between groups, whereas FVC increased to a greater extent in young adults (P < 0

292 mmHg; 95% CI = 1-9) were increased, whereas FVC (-0.2 mL min(-1) mmHg(-1) ; 95% CI = -0.0 to -0.4) a

293 rovements in some PROs, QILD, and QLF, while FVC% worsening >/=MCID was associated with statistically

294 p to 3 months was negatively associated with FVC at 12 and 18.

295 or early-life exposures were associated with FVC decline.

296 dentified a novel DPP10 SNP association with FVC that was not detectable in much larger studies ignor

297 teristics further revealed associations with FVC % predicted, and oral corticosteroid or antileukotri

298 nes known to influence lung development with FVC and FEV(1)/FVC.

299 increased risk of death versus patients with FVC >=80% (HR, 1.72; 1.05-2.83).

300 ion of rs11693320-an intronic DPP10 SNP-with FVC when incorporating an interaction with DHA, and the